EUCTR2007-007103-32-SE进行中（未招募）不适用
A randomized, double blinded placebo controlled study to investigate antimicrobial efficacy and safety following topical application of DPK-060. Final protocol dated 2007-12-19. CRO protocol no. Q-27318. Final protocol incorporating amendment 1 dated 2008-08-28. Amendment 2 dated 2008-10-01.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- DermaGen AB
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Fulfilling the diagnostic criteria of Williams (Williams, 1994a, 1994b, 1994c, 1996) for AD (disease involvement must similarly affect the flexor regions of both arms/legs/shoulder)
- •For inclusion in Part A of the study, patients must have treatable eczematous lesions of a total area of at least 100 cm2
- •Outpatients aged between 18 and 65 years inclusive. Females must use an accepted form of contraception such as a stable dose of oral contraceptive or a hormone implant for at least three months prior to dosing or barrier methods (i.e. intrauterine device, diaphragm, combination of a condom and spermicide) for the duration of the trial
- •No clinically important abnormal physical findings at the screening examination as judged by medical history, physical examination, ECG, vital signs, hematology, clinical chemistry
- •Has been given written and verbal information and has had opportunity to ask questions about the study
- •Signed consent (written) to participate in the study
- •Fulfilling the diagnostic criteria of AD
- •For inclusion in Part B of the study, patients must have treatable eczematous lesions of a total area of at least 25 cm2.
- •Outpatients aged between 18 and 65 years inclusive. Before the PK data from the first set of 10 patients have been evaluated fertile females will not be eligible. Thereafter if approved by the MPA fertile females may be included and must use an accepted form of contraception such as a stable dose of oral contraceptive or a hormone implant for at least three months prior to dosing or barrier methods (i.e. intrauterine device, diaphragm, combination of a condom and spermicide) for the duration of the trial. Pending the MPA decision, patients (excluding fertile females) will continuously be recruited into the study and PK samples will be collected. Non-fertile females must fulfill one of following:
- •- Amenorrhea and no pregnancy in the last 12 months prior to enrolment combined with FSH levels in the postmenopausal range, as judged by the investigator
- •-Documentation of being irreversible surgically sterile, i.e. hysterectomy or bilateral oophorectomy (but not tubal ligation)
- •No clinically important abnormal physical findings at the screening examination as judged by the investigator
- •Has been given written and verbal information and has had opportunity to ask questions about the study
- •Signed consent (written) to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded if any of the following criteria are present:
- •Significant clinical illness, within the 2 weeks prior to first dose, which could affect the outcome of the study
- •Previous local or systemic antimicrobial therapy within the last 4 weeks prior to the first application of the investigational product (DPK-060 1% ointment)
- •Existence of any surgical or medical condition which, in the judgment of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Patients who have had systemic treatment for AD or other topical or transdermal treatments (such as nicotine, hormone replacement therapies) on the site of eczema within 14 days prior to first application of DPK-060 1% ointment and/or topical treatment with tar, any corticosteroid, topical immunomodulators or oral treatment with any corticosteroids within 14 days prior to first application and/or oral anti-histamines within 14 days of the first dose.
- •A need for any other medication during the period 0 to 7 days before entry to the study, (excluding the oral contraceptive pill for females) except those deemed by the principal investigator / clinical investigator not to interfere with the outcome of the study
- •Diagnosis of other skin diseases, which in the opinion of the investigator, are likely to adversely affect the outcome of study
- •History or evidence of significant cardiac, renal, hepatic or endocrine disease
- •Significant hypersensitivity or allergy, as judged by the investigator
- •Immunocompromised patients
- •Lice or scabies
- •Tinea corporis
- •Hypersensitivity to the ingredients of the vehicle
- •The presence of prominent tattoos at sites of application of DPK-060 1% ointment
- •Donation of blood, exceeding 450 ml, during the 3 months prior to first dose
- •Participation in a clinical study during the 12 weeks prior to first dose
- •Ongoing alcohol or drug abuse
- •Positive pregnancy test or lactation
研究者
相似试验
尚未招募
3 期
To evaluate the benefits and side effects of garlic extract in the patients with mild hypertension who are under standard care of treatment.CTRI/2023/12/060512Sami Sabinsa Group Limited
已完成
不适用
A clinical trial to evaluate the safety and efficacy of Lycq® on subjects with high serum cholesterol levelsCTRI/2013/06/003786Edio Healthcare AB80
进行中（未招募）
1 期
A study on healthy volunteers investigating if simvastatin affects the body ability to reduce stress from oxygen (oxidative stress)Simvasatins effect on Oxidative StressMedDRA version: 17.0Level: SOCClassification code 10022891Term: InvestigationsSystem Organ Class: 10022891 - InvestigationsEUCTR2014-000959-92-DKDepartment of Clinical Pharmacology Q40
已完成
4 期
Sttudy to evaluate the efficacy and safety of KSM- 66 Ashwagandha on Subclinical Hypothyroidism patientsCTRI/2016/05/006903Shri Karthikeya Pharma50
进行中（未招募）
4 期
A Randomized double-blind placebo controlled study to Evaluate Prophylactic effects of Silodosin on Postoperative Urinary RetentioPost-operative urinary retention is common in inguinal henia and anorectal surgery. Alpha blocker can reduce post operative urinary retentionSilodosin,POURTCTR20191226003Ramathibodhi Hospital268